Ardelyx (ARDX) Insider David Mott Buys 39,715 Shares
Recent regulatory filings show insider buying activity alongside ongoing updates from wall street analysts covering the biotech firm.
Reviewed by automated data checks against the source filing. How we make and check alerts
David Mott bought 39,715 shares of Ardelyx, Inc. ($ARDX) on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ARDX is up 9.0% after 1 week, down 9.7% after 1 month and down 45.5% to date (from the $5.67 close on Jun 16, 2026).
ARDX
Ardelyx, Inc.
Key Points
- David Mott picked up 39,715 shares of Ardelyx, Inc. (NasdaqGM: ARDX) on June 16, 2026, highlighting notable insider transaction volume.
- The biotechnology company trades near its 200-day moving average of $5.75, backed by a forward PE ratio of roughly 11.7.
- Wall street firms like Wedbush, Piper Sandler, and Citigroup maintain positive views on the stock with a consensus strong buy rating.
Get $ARDX trade alerts by text
We text you when insiders, Congress or big funds trade $ARDX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Ardelyx, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Ardelyx, Inc.
On June 16, 2026, filing details reveal that David Mott acquired 39,715 shares of Ardelyx, Inc. (NasdaqGM: ARDX). This addition stands out for its size within the biotech firm, occurring alongside other recent insider movements. Just a couple of days later on June 18, 2026, Laura Williams, who serves as the Chief Patient Officer, parted with 81,898 shares at an average price of $5.99 for a total value of $490,569.02 under a planned trading program. Another identical block of 39,715 shares was recorded for Merdad Parsey on the same June 16 date.
Stock Performance and Valuation Context
Shares of Ardelyx change hands around $5.84, resting near the company's 200-day moving average of $5.75. The stock has experienced a wide 52-week trading span, reaching a low of $3.33 and climbing up to $8.40. With a market capitalization sitting near $903.7 million, the equity trades with a forward P/E ratio of 11.7. Its 50-day moving average sits lower at $4.26, while the company maintains a beta of 0.69, pointing to modest price swings relative to the broader market.
Recent Analyst Updates and Price Targets
Financial firms have actively updated their outlooks on Ardelyx shares through August 2026. On August 19, Wedbush reiterated its outperform rating while keeping a $9.00 price target, following a similar note the day before. Piper Sandler maintained an overweight rating on August 17 while adjusting its target to $15.00. Citigroup kept a buy rating on August 10 with an 11-dollar target. TD Cowen maintained a buy rating with a $10.00 target on August 7, and BTIG kept a buy rating with a $14.00 target on the same day. Overall, the stock holds a consensus recommendation of strong buy with a mean target price of $12.90 across ten analyst opinions.
Understanding the Business
Ardelyx focuses on discovering, developing, and commercializing targeted medicines to address serious unmet medical needs. Its commercial portfolio includes therapies designed for adult patients dealing with specific gastrointestinal and kidney conditions in the United States and international markets. The Waltham-based company continues to advance its treatments as key revenue drivers while monitoring commercial adoption.
What to Watch at Ardelyx, Inc.
Market participants will look toward the next earnings release scheduled for October 29, 2026, for further updates on commercial progress and financial health. Insider transaction reports filed under SEC guidelines provide a backward-looking view of executive sentiment and do not guarantee future performance.
Related Filing Alerts
Source: David Mott's Form 4 filing on $ARDX (Jun 16, 2026). Find the original filing: ARDX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts